Indiva Shapes Strong Brand Identity in Canada, Eyes Emerging European Market
February 6th, 2019
Exclusive, News, Top News
INDIVA Limited (TSX-V:NDVA) is a licensed supplier of high quality, medical-grade cannabis located in London, Ontario. Recognizing that many consumers are looking for alternatives to smoking, it made a number of exciting strategic moves throughout 2018 to diversify its brand. The company went public in December of 2017, currently has $24 million on the balance sheet with a $46 million market cap, and its fully-funded facility expansion project is nearing completion.
Indiva stresses quality over quantity, and intends to become a global brand recognized for high quality cannabis products and excellent client services. The INDIVA brand includes pre-rolls, capsules, and accessories, and the company has developed a range of other products in order to hit the ground running when Canada’s cannabis regulations are further liberalized later this year.
Indiva’s London facility includes four state of the art grow rooms and the $13.7 million, fully-funded, expansion currently underway will result in a 40,000 square foot facility with up to eight more rooms for cultivation, extraction, product manufacturing, and even a retail space. Indiva’s cannabis flower is produced using aeroponics, a soil-less process in which plant roots are suspended in air and misted with all the nutrients they need, producing larger yields and a much cleaner product while being environmentally friendly.
Bhang’s Award-Winning Offering
In April of 2018, the company announced a 50/50 joint venture with Nevada-based Bhang Corporation, an award-winning producer of cannabis and CBD edibles and concentrates, which will be managed by Indiva and enable the manufacture and sale of Bhang products in Canada, as well as the export of its products internationally. Through the agreement, Indiva gained exclusive access to Bhang’s portfolio of products including the most awarded line of chocolate bars in the world, gummies, oral sprays, isolates, vapes and vape cartridges, and a range of accessories. The company also announced a 4.9% stake in Bhang, giving it its first entry into the legal US adult-use market.
Later that same month, Indiva announced the company has a 14% stake in and exclusive license agreement with DeepCell Industries – a Seattle-based technology development company focusing on material science, microfluidics, and cannabinoid molecule discoveries – giving it the exclusive right to manufacture and market DeepCell’s entire line of innovative products produced through its patented Crystal Fusion technology. Crystal Fusion mechanically fuses cannabinoids with sugar or salt, producing a “flexible edible” with which consumers can infuse their food and beverages with flavour as well as THC or CBD. The resulting products are sold as Ruby Cannabis Sugar and Ruby Cannabis Salt.
All Bhang products and Ruby sugars and salts will be cross-branded in Canada – “Powered By INDIVA”.
In September, Indiva entered into a Cannabis Concentrate Program Agreement with MediPharm Labs, Inc. a pioneer in the cannabis industry and the first Canadian licensed producer of cannabis oil under the Access to Cannabis for Medical Purposes Regulations. Indiva will supply dried cannabis to MediPharm, which it will use to produce cannabis oil. MediPharm may provide cannabis oil to Indiva or to other licensed producers at the direction of Indiva, which may release the cannabis extract for use by MediPharm. The program was established at no capital cost to Indiva, but MediPharm will charge the company processing fees for the oil produced, and the revenue on sales of oil by MediPharm will be shared between MediPharm and Indiva.
Denmark, Gateway To European Cannabis Market
At the end of November, Indiva announced it had signed a non-binding letter of intent with AEssense Europe for the acquisition of 100% of a medical cannabis cultivation and handling license in Denmark. AEssense Europe received its license – one of only twelve granted – from the Danish Medicines Agency on January 12, 2018. The Danish Parliament legalized medical cannabis through a unanimous vote on January 1, 2018, and is poised to become one of Europe’s leading producers of medical cannabis. Denmark will serve as the company’s gateway to the European market, which is predicted to be larger than the US and Canadian markets combined.
Indiva will pursue the cultivation and worldwide distribution of EU-GMP certified medical cannabis and cannabis-derived products, and intends to incorporate a wholly-owned subsidiary, Indiva Europe, to finance and manage the European operations. In collaboration with AEssense, Indiva Europe plans to construct an indoor grow facility based on AEssense’s proprietary AEtrium fully automated aeroponic grow platform, enabling Indiva to produce consistent, ultra-clean, premium pharmaceutical quality cannabis product compliant with GACP and EU-GMP standards. Sites have been identified to begin construction of a 1,000 square foot research lab as part of the production facility, with ample room for scaled expansion. Indiva will have the exclusive right to all cannabis-related production, and will leverage the Denmark license for the importation of EU-GMP cannabis into the Danish and European markets.
Indiva is a community-minded company, helping first responders and veterans, chronic illness support organizations, and other community initiatives, and gives twenty cents from every gram of Indiva-branded flower and oil product to support mental and physical health initiatives and organizations across Canada. The company’s Master Grower, Pete Young, is well known for his cannabis activism, founded the London Compassion Society in the mid-90’s, and is a respected advocate of patients’ rights.
Indiva is worth watching as the company continues to diversify from a supplier of medical cannabis to a manufacturer and retailer of high margin cannabis-derived and pre-packaged products, partner with innovative companies like Bhang and Deepcell, and especially as its reach into larger foreign markets expands.
For more information, please visit: https://www.indiva.com/
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Media Group (CannabisFN), owned and operated by CFN Enterprises Inc. (OTCQB: CNFN), is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.